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ABSTRACT 
Purpose:  
Efforts to promote arteriovenous fistulas (AVFs) have been successful in increasing 
the prevalence of AVF use as the primary vascular access for haemodialysis HD.  
Sustained preference for AVF use may not be the most appropriate vascular access 
choice for all patient groups. Arteriovenous grafts (AVGs) offer advantages of earlier 
use and lower primary failure rates compared to AVFs so may be preferable for 
patients where short term vascular access is needed. This study was designed to 
assess comparative mortality in different age groups following AVF formation.  
Methods:  
A prospective cohort of patients having AVF creation was recruited. Patients were 
subdivided into three age groups; Group A: < 50 years; Group B: 50-74 years and 
Group C:  75 years.  Survival curves and Cox regression analysis was performed on 
each of these groups.  
Results:  
One hundred and thirty-four patients (n=134) were recruited into the study. The 
prevalence of diabetes increased significantly with age. As expected, mortality was 
higher in older age groups (log rank (mantel cox) 19.227; p = 0.0001). Mortality rates 
at one year were 0% in group A, 12.5% in group B and 29.1% in group C. Medium 
term mortality at four years  was 7.9% in group A, 39.1% in group B and 54.8%% in 
group C.  
Conclusions:  
We found a significantly higher mortality rate in patients ≥75 years in comparison to 
those <75 years. The choice of vascular access modality should be tailored to the 
individual with particular reference to the patient’s expected survival.  
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INTRODUCTION 
The prevalent use of arteriovenous fistulas (AVFs) has increased reflecting initiatives 
such as Fistula First (http://www.fistulafirst.org/) and promotion of AVFs as the 
vascular access of choice in national guidelines.(1,2,3,4) The improvement in AVF 
prevalence is a welcome trend however older patients could be disadvantaged by 
repeated unsuccessful attempts at surgical AVF creation and resulting 
overdependence on central venous catheters (CVCs).(5) The age structure of the 
end-stage renal disease (ESRD) population has changed considerably over the past 
20 years with an increasing proportion of older patients (>75 years) receiving 
dialysis.(6,7,8) Furthermore the progression of chronic kidney disease is typically 
slower and less predictable in older patients. This can mean in practice that is 
difficult to ensure timely provision of vascular access for older patients. The 
significant increase in the number of elderly dialysis patients and the unique 
challenges they represent for vascular access provision are poorly reflected in 
guidelines regarding vascular access formation. (1,2,3,4) This is also emphasised in 
a recent review by Fassett and colleagues(9) of palliative care in ESRD suggesting 
there is a paucity of robust evidence to predict the outcomes in elderly patients who 
commence dialysis and therefore decisions regarding their best management remain 
difficult.   
Worldwide, the number of elderly patients with ESRD commencing haemodialysis is 
rising. In the USA, since 2000, the adjusted incident rate for dialysis in patients aged 
≥75 years has increased by 12.2%.(6) In Canada, the number of incident patients 
with ESRD aged ≥75 years doubled between 1996 and 2005 whilst the number of 
incident patients with ESRD aged 20–64 years has decreased in the corresponding 
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years.(7) In the UK, from 2005 to 2008, the number of patients on dialysis aged ≥65 
years increased by 29% compared with an increase of only 16% in those aged 18–
65 years.(8) 
Important factors associated with AVF failure in those patients >67 years of age 
include increasing age, female gender, black race, diabetes, cardiac failure and 
shorter pre-ESRD nephrology care.(10)   
Optimal timing of referral for AVF formation is a complex issue in the management of 
patients with ESRD. Advanced age has been shown to be a risk factor for late 
referral to nephrologist, increased use of CVCs and increased likelihood of hospital 
admission, septicaemia and higher mortality.(11,12) It would therefore be important 
to stratify these patients into groups and decide dialysis needs according to 
individual profiles and patient preferences rather than a Fistula First “one size fits all” 
policy.  
 
We sought to prospectively assess the age-related mortality of patients following 
surgical creation of an AVF and identify the factors contributing to higher mortality 
rates.   
 
SUBJECTS AND METHODS 
A prospective cohort study was designed and recruited consecutive patients 
undergoing single incision (radiocephalic, brachiocephalic and first stage 
brachiobasilic) AVF formation between 8th April 2009 and 30th September 2009. 
Patients are referred to the vascular access unit following weekly multi-disciplinary 
team discussions identifying patients who are showing rapid progression of renal 
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disease with a glomerular filtration rate of < 15 mL/min/1.73m2 or < 20 
mL/min/1.73m2 for patients with diabetes. All surgery was performed in a single 
centre (Queen Elizabeth Hospital, Birmingham, UK) and all operations were carried 
out by or under the direct supervision of four consultant surgeons. Information was 
collated in a vascular access database and included patient age, past medical 
history, pre-operative haemoglobin concentration, international normalised ratio, 
systolic and diastolic blood pressures, anticoagulant medications, grade of operating 
surgeon, type of AVF formed, pre-operative vessel measurements made with 
Doppler ultrasound assessment and dialysis status.  Vessels considered suitable for 
AVF formation were based on intraluminal size criteria (2 mm for artery and 2.5 mm 
for vein) and vessel patency. This patient cohort was followed up until 10th August 
2013 with outcomes documented focusing on date of death. No system is currently 
in place within our unit for surveillance of AVF which are found to have achieved 
radiological adequacy at six weeks but not yet used for dialysis. The study was 
approved by local audit review board (CARMS-11315) where specific patient 
consent was not deemed necessary as it was non-interventional and observational. 
Data was collected and analysed from the electronic patient database using clinical 
data collected as standard and not study specific. This database is also updated 
from primary care to ensure all deaths of patients are recorded. Patients were 
subdivided into age groups accordingly; Group A: < 50 years; Group B: 50-74 years 
and Group C:  ≥75 years of age.  Survival analysis was then performed using SPSS 
20 for each of these age groups. Cox regression analysis was used to identify 
clinical factors which impacted upon survival. 
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RESULTS  
A total of 147 patients were included in the study. Nine patients were excluded after 
they underwent a second stage brachiobasilic operation. Two patients were 
excluded since their operations were for complications of a previously formed fistula 
(ligation of their AVF; one for aneurysmal development and one for vascular steal). 
Two further patients were excluded since they had an AVG inserted. This left 134 
patients available for survival analysis. Seven patients had their operations 
performed under general anaesthetic and 127 patients underwent their procedure 
under local anaesthetic.  
 
Cause of end-stage renal disease (ESRD) 
Of the 134 patients included, 32 (23.9%) had diabetes documented as a cause of 
ESRD. Twenty-three (17.2%) had an unknown cause, 17 (12.7%) had 
glomerulonephritis, 11 (8.2%) had hypertension, 6 (4.5%) had small kidneys, 8 
(5.9%) had polycystic kidney disease, 5 (3.7%) had reflux nephropathy and 7 (5.2%) 
had renovascular disease documented as the cause of ESRD. The remaining 25 
(18.7%) had documented diagnoses of amyloidosis, myeloma, obstructive 
nephropathy, abdominal aortic aneurysm repair, bilateral nephrectomies for renal cell 
carcinoma, calcineurin inhibitor toxicity, juvenile nephronophthisis, nephrolithiasis, 
microscopic polyangiitis, post cystectomy for transitional cell carcinoma, renal 
dysplasia, renal tuberculosis and scleroderma. 
 
Ethnicity 
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Eighty-nine (66.4%) patients were white, 29 (21.6%) were Indo-Asian, 12 (9.0%) 
were black, two (1.5%) were of mixed ethnicity and two (1.5%) patients were 
Chinese.  
 
Past medical history and medications 
Prevalence of hypertension and diabetes for the entire cohort was 68.7% (92 
patients) and 35.1% (47 patients) respectively. Eleven patients (8.2%) had 
previously undergone a renal transplant and six (4.5%) had a documented history of 
peripheral vascular disease. Thirty-nine patients (29.1%) were on aspirin, seven 
(5.2%) were on clopidogrel and 16 (11.9%) were on warfarin.  
 
Types of arteriovenous fistula formed 
Sixty two patients (46.3%) had radiocephalic AVFs, 54 (40.3%) had brachiocephalic 
AVFs and 18 (13.4%) had first stage brachiobasilic AVFs formed.  
 
Dialysis status 
Sixty-one patients (45.5%) were pre-dialysis, 73 were (54.5%) had already 
commenced dialysis. 
Function 
Early patency defined as a patent AVF at six week postoperative review was 
established in 113 (84.3%) patients and 77 (53.8%) subsequently used for dialysis. 
No attempt was made to monitor or salvage AVF which failed prior to the six week 
post-operative review.  
 
Sub-group analysis 
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Table I shows the demographics of patients according to age groups. Thirty-eight 
(28.4%) patients in group A; 65 (48.5%) in group B; and 31 (23.1%) in group C. 
 
Survival analysis 
As expected, mortality was significantly higher with increasing age (log rank (mantel 
cox) 19.227; P = 0.0001). Figure 1 shows mortality rates for each age group. 
Mortality rates over 4 years were 7.9% in group A, 38.5% in group B and 54.8% in 
group C.  The cumulative survival for each group from year 1 to year 4 is shown in 
Table II. Mortality rates were not significantly different if patients had commenced 
dialysis by the time of AVF creation or not. Cox regression analysis for the different 
variables confirmed that age and diabetes are associated with increased risk of 
death. In comparison to group A, group B (HR 5.1, CI 1.5-17.2; P=0.009) and group 
C (HR 8.7, CI 2.5-30.5; P=0.001) had an increased risk of death. The increased 
mortality risk with diabetes was not statistically significant (HR 1.5, CI 0.8-2.7; 
P=0.197). Gender, ethnicity, hypertension were not associated with an increased risk 
of death. Peripheral vascular disease was associated with an increased risk of death 
(HR 2.9, CI 1.0-8.1; P=0.043) however less than 5% of patients had documented 
history of peripheral vascular disease.  
 
DISCUSSION 
This prospective study demonstrates that older patients referred for AVF surgery 
have poorer survival compared to younger patients during a four year follow up 
period. Although this finding is to be expected, reflecting the impact of advancing age 
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with associated multiple co-morbidities upon patient survival, it is relevant when 
deciding on the optimal vascular access procedure for older patients.  
The UK Renal Registry 16th Annual Report (13) states that the most common 
primary renal diagnosis for ESRD in the 2012 incident cohort was diabetes (25.6%), 
followed by other (17.7%), unknown aetiology (15.9%), glomerulonephritis (14%), 
hypertension (7.4%) and polycystic kidney disease (6.7%).  UK Renal Registry data 
also shows 70.8% of incident renal replacement therapy patients to be white, 22.7% 
to be South Asian, 5.1% to be black and 1.4% other.  The causes of incident ESRD 
and background ethnicity are similar in our cohort.  For instance, the prevalence of 
diabetes (35.1%) and peripheral vascular disease (4.5%) in our cohort is very similar 
to UK Renal Registry data showing an overall prevalence of diabetes at 34.8%, and 
claudication at 6%. Our data is therefore largely representative of the UK population 
reported in nationally published annual data.(13)  
In this cohort a higher number of radiocephalic AVFs (46.3%) were formed than 
brachiocephalic AVFs (40.3%) and first stage brachiobasilic AVFs (7.5%). This range 
of AVFs formed is reflective of a larger retrospective cohort published by Weale and 
colleagues (14) where more radiocephalic (53.9%) AVFs were formed than 
brachiocephalic AVFs (46.1%).  
Sub-group analysis 
Diabetes was statistically more prevalent in the over 50 years of age groups. 
Hypertension was found to be prevalent throughout all age groups and antiplatelet 
and antithrombotic agent use increased with increasing age undoubtedly reflecting 
the higher incidence of cardiovascular co-morbidities seen in the aging population. 
Ethnic background was similar in all age groups. Age did not impact on the type of 
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AVF created however in our centre we use Doppler ultrasound measurements to 
assess blood vessel suitability for AVF formation and therefore do not discriminate 
by age alone.  
Oliva and colleagues (15) report a four year survival of haemodialysis patients over 
75 years of age as 39.6%. They compared mortality rates between less than 60 
years, 60-75 years and 75 years and over. They found a significantly higher mortality 
in elderly (>75 years) patients with a cumulative survival of 83.1%, 68.3%, 53.5% 
and 39.6% after years 1, 2, 3, and 4.  We found our cumulative survival rates in 
patients over 75 years to be 71.0%, 58.1%, 51.6% and 41.9% after years 1, 2, 3 and 
4 respectively. Interestingly, Oliva and colleagues admit to some biasing of the data 
since they excluded the 71 patients who died within 90 days of commencing 
haemodialysis. Our data shows that a substantial number of deaths occur early in 
patients being referred for vascular access procedures. Approximately 42% of those 
over 75 years of age died within 2 years of being referred for a fistula. UK life 
expectancy data published in 2002 states that at 70 years of age males can expect 
to live for a further 14.7 years and females 17 years. Similarly for persons of 80 
years of age life expectancy is 7.7 years for males and 9.1 years for females. (16) 
The median survival of our cohort over 75 years is approximately 3 years confirming 
a shorter life expectancy in the presence of ESRD for those patients referred for 
fistula formation. 
The high primary failure rate for AVFs is a very important issue in the elderly 
population. The length of time between referral for access formation and surgical 
procedure has been reported by Rayner and colleagues(17) to be longer than four 
weeks in 60% of patients referred, a conclusion that has been subsequently 
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supported by Ethier at al. (18) The major advantage of CVCs is that they can be 
used immediately for dialysis. This advantage has been extended more recently to 
AVGs specifically designed for use in vascular access surgery as some may be 
ready for use within 24 hours of insertion. The combined advantage of early 
cannulation of an AVG and reduced incidence of bloodstream infections (compared 
to CVCs) means that an AVG may offer the best compromise for vascular access in 
older patients with limited expected survival.   
A critical point emphasized in the paper by Allon and Lok (19) is the inclusion of 
primary failures in the analysis of AVF compared to AVG. Once primary failure is 
included overall outcomes are equivalent or better for AVGs compared to AVFs up to 
18 months following the initial vascular access surgery. AVGs have been shown to 
have significantly less primary failures, require fewer interventions to achieve 
patency and are associated with shorter duration of CVC dependence and CVC-
related infections. AVGs are however associated with poorer cumulative survival 
compared with AVFs and require more interventions to maintain patency. (20) These 
conclusions are supported by Oliver at al. (21) who observed a longer period of 
CVC-dependence and superior patency of AVFs overall but comparable survival 
when primary failures are included. Indeed, a recent report from the USA has shown 
the Fistula First Breakthrough Initiative implementation to have increased the use of 
CVCs with any increased emphasis on in the placement of AVFs coming at the 
expense of AVGs rather than CVCs. (22) This has been argued to be a reflection of 
the increased use of CVCs as a temporary bridging measure to allow maturation of 
AVFs. (23) 
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The factors shown by Oliva and colleagues to be associated with an increased 
mortality were low BMI, CVC as initial vascular access, arterial hypertension, 
congestive heart failure, late referral to nephrologist, serum albumin level below 3.5 
g/dL, Kt/V <1.2 and time of dialysis session less than 180 minutes. The multivariate 
model found that congestive heart failure, Kt/V <1.2 and serum albumin level <3.5 
g/dL remained as independent predictors of mortality in those dialysis patients 
greater than 75 years of age. (15) We found in our cohort that age and peripheral 
vascular disease to be the only factors associated with significantly increased risk of 
death.  
Limitations 
This is a relatively small cohort of patients however we have shown the 
demographics to be representative of nationally published reports. A larger national 
cohort would further support the conclusions drawn here and allow for identification 
of patient related factors which correlate with a less than two year survival.  
Conclusion 
Our results show that elderly patients (>75 years) are much more likely to die within 
a 2 year period than those less than 75 years of age. In an older population a more 
tailored approach to vascular access creation is necessary. This study supports an 
AVG as a suitable first access by demonstrating that survival after AVF formation, 
whether successful or not is limited and rapid access from an AVG, with avoidance 
of CVC, is a pragmatic alternative approach to providing vascular access for elderly 
haemodialysis patients.   
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Figure 1: Time to death following formation of fistula according to age.
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Table I: Demographics of patients according to age groups.  
 Group A 
(<50 years) 
Group B 
(50–74 years) 
Group C 
(>75 years) 
P value 
Student’s t-test 
Number of patients (%) 38 (28.4) 65 (48.5%) 31 (23.1%) - 
Sex, male % 60.5 66.2 74.9 0.488 
Ethnicitya 
W/A/B/M/C 
23/10/4/1/0 43/13/6/1/2 23/6/2/0/0 0.832 
Diabetes % 13.2 42.2 48.4 0.003 
Hypertension % 78.9 65.6 64.5 0.302 
Previous transplant % 18.4 6.2 0 0.15 
Peripheral vascular 
disease % 
2.6 6.7 3.2 0.644 
Warfarin % 7.9 15.6 10 0.472 
Aspirin % 13.2 32.8 43.3 0.019 
Clopidogrel % 2.6 1.6 16.7 0.007 
Type of fistula formedb 
RCF/BCF/BBF 
18/14/6 29/26/10 15/14/2 0.765 
Pre-dialysisc  
?/Pre/Post 
3/13/22 5/25/35 2/16/13 0.673 
 
21 
 
21 
 
aW=White; A=Asian; B=Black; M=Mixed; C=Chinese. 
bRCF=Radiocephalic fistula; BCF=Brachiocephalic fistula; BBF=First stage 
brachoibasilic fistula.  
c?=unknown dialysis status; Pre=pre-dialysis; Post=commenced dialysis. 
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Table II: Cumulative survival (%) at the end of the year 
 
Years 1 2 3 4 
Group A (<50 yr) 100 97.4 94.7 92.1 
Group B (50-74 yr)  87.5 78.1 70.3 60.9 
Group C (>75yr) 70.9 58.1 51.6 45.2 
 
 
